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Background: To determine the comparative effectiveness and costs of a CT-strategy and a stress-
electrocardiography-based strategy (standard-of-care; SOC-strategy) for diagnosing coronary artery disease
(CAD).
Methods: A decision analysis was performed based on a well-documented prospective cohort of 471 outpa-
tients with stable chest pain with follow-up combined with best-available evidence from the literature.
Outcomes were correct classiﬁcation of patients as CAD− (no obstructive CAD), CAD+ (obstructive CAD
without revascularization) and indication for Revascularization (using a combination reference standard),
diagnostic costs, lifetime health care costs, and quality-adjusted life years (QALY). Parameter uncertainty
was analyzed using probabilistic sensitivity analysis.
Results: For men (and women), diagnostic cost savings were €245 (€252) for the CT-strategy as compared to
the SOC-strategy. The CT-strategy classiﬁed 82% (88%) of simulated men (women) in the appropriate disease
category, whereas 83% (85%) were correctly classiﬁed by the SOC-strategy. The long-term cost-effectiveness
analysis showed that the SOC-strategy was dominated by the CT-strategy, which was less expensive (−€229
in men, −€444 in women) and more effective (+0.002 QALY in men, +0.005 in women). The CT-strategy
was cost-saving (−€231) but also less effective compared to SOC (−0.003 QALY) in men with a pre-test
probability of ≥70%. The CT-strategy was cost-effective in 100% of simulations, except for men with a pre-
test probability ≥70% in which case it was 59%.
Conclusions: The results suggest that a CT-based strategy is less expensive and equally effective compared to
SOC in all women and in men with a pre-test probability b70%.© 2012 Elsevier Ireland Ltd. All rights reserved.1. Introduction
The current guideline still recommends stress electrocardiogra-
phy(X-ECG) as ﬁrst line diagnostic test for patients with stable chest
pain [1]. However, the diagnostic accuracy of X-ECG is limited [2].
Coronary CT angiography(CCTA) is an alternative modality for
diagnosing coronary artery disease(CAD). Its diagnostic accuracy
compared to catheter-based coronary angiography(CAG) in highlyby internal funding through a
ity Medical Center, Rotterdam.
nizations. The funding organi-
f this study; data management
authorization for submission.
gy andRadiology, ErasmusMC—
CA Rotterdam, The Netherlands.
unink).
Ltd. All rights reserved.selected patients has been studied extensively [3–7], demonstrating
that CCTA is reliable in ruling out CAD (sensitivity 95–100%). Further-
more, previously published decision analyses indicate that CCTA as
triage test in patients referred for CAG is cost-effective in patients
with a low-intermediate probability of disease [8–10].
Recently, results from a Dutch outpatient chest pain clinic were
published [11,12]. Patients with stable chest pain were evaluated by
X-ECG, CT calcium scoring, and CCTA. Results suggested that CT calci-
um scoring, selectively followed by CCTA could replace X-ECG as ﬁrst
line diagnostic test. However, long-term effectiveness and costs of
CCTA compared to standard-of-care (SOC) in outpatients presenting
with chest pain remain unclear.
Ideally, a large randomized controlled trial (RCT) comparing a CT-
based strategy to SOC should be performed to evaluate comparative
effectiveness and costs. Exploration of diagnostic strategies and pre-
liminary estimates of outcomes can help design such a trial and can
justify the investment of research resources. Furthermore, trial results
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diagnostic testing decisions have to be made. A decision-analytic
approach summarizing the evidence can be helpful in such situations.
Aim of this study was to determine the comparative effectiveness
and costs of a hypothetical CT-strategy compared with SOC using a
decision-analytic approach combining data from a well-documented
prospective patient cohort with the best-available evidence from
the literature.
2. Materials and methods
2.1. Patient population
The model was based on a prospective clinical cohort [11] of 471 patients who
presented with stable chest pain and no history of CAD. All patients were scheduled
for X-ECG and CCTA (Table 1). During a mean follow-up (complete in 90%) of
2.6 years, 44 major adverse cardiovascular events (MACE: cardiac death, myocardial
infarction, unstable angina requiring hospitalization, and revascularization) occurred
in 30 patients [13] (Table A1). The study complied with the Declaration of HelsinkiTable 1
Baseline characteristicsa, diagnostic test resultsa, cost estimates and radiation exposure.
Baseline characteristics Value
Age, mean(SD) 56 (10)
Female: male 227:224 (0.48:0.52)
Risk proﬁle
Nicotine use 138 (0.29)
Hypertension 233 (0.49)
Diabetes 68 (0.14)
Dyslipidaemia 28 (0.59)
Family history of cardiovascular disease 214 (0.45)
Chest pain [36]
Typical 146 (0.31)
Atypical 251 (0.53)
Non-anginal chest pain 74 (0.16)
Catheter-based coronary angiography 98 (0.21)
≥50% stenosis, any vessel 57/98 (0.58)
≥70% stenosis, any vessel 29/98 (0.30)
Percutaneous coronary intervention 46 (0.10)
Coronary bypass graft surgery 13 (0.03)
X-ECG Not performed 48/471 (0.10)
Normal 190/423 (0.45)
Non diagnostic 140/423 (0.33)
Abnormal 93/423 (0.22)
CCS Not performed 8/471 (0.02)
Mean CCS (median) 206 (15)
Range 0-4817
Interquartile range 0-145
CCTA Not performed 16/471 (0.03)
Non-diagnostic 3/471 (0.01)
No obstructive CAD 311/471 (0.66)
Obstructive CAD (≥50%) 141/471 (0.34)
Severe CAD (3VD, LM, prox. LAD) 48/141
CAG performed 121/471 (0.26)
≥50% stenosis, any vessel 71/121 (0.59)
≥70% stenosis, any vessel 34/121 (0.28)
Percutaneous coronary intervention 53/471 (0.11)
Coronary artery bypass graft surgery 18/471 (0.04)
Cost estimates
(euros)
Radiation exposure
(mSv)
Exercise tolerance test (Expert opinion) 106 –
Coronary calcium score [8] 64 0.8
CT coronary angiography [8] 206 4.7
Single photon emission CT
(Expert opinion)
545 12
Cathether-based coronary
angiography [8]
1394 7.0
Percutaneous coronary
intervention [37]
5000 15
Coronary bypass graft surgery [37] 14,000 –
Results are shown as numbers (proportion of total) unless stated otherwise. X-ECG,
exercise electrocardiography; CCTA, coronary computed tomography angiography;
CAG, catheter-based coronary angiography.
a Modiﬁed with permission from Nieman et al. [11].and the ethical committee at our institution approved the study. Informed consent
was obtained from all patients.2.2. Decision model
We developed a decision model (in DATA Pro 2009 Suite, TreeAge Software Inc,
Williamstown, MA, USA) to evaluate the comparative effectiveness and costs of a
hypothetical CT-based strategy compared to an X-ECG-based strategy (reﬂecting
standard-of-care; SOC-strategy). Short-term diagnostic outcomes were modeled with
a decision tree (Figs. 1, 2). Long-term prognosis (lifetime) was modeled using a
Markov-Model (Figure A1). Model parameters were based on the clinical cohort with
follow-up combined with best-available evidence from the literature (Table A2, A3).
See supplementary material for a detailed model description.
Model probabilities for diagnostic test results were based on the clinical cohort and
conditional on the “underlying truth”, sex, and the pre-test probability. To model the
“underlying truth”, a disease category was assigned to all patients in the cohort: No
obstructive CAD (CAD−), Obstructive CAD (CAD+) or Revascularization (Revasc)
(Fig. 3), which represents the true disease status at baseline. This was based on
CAG(if performed), the treatment initiated and CCTA otherwise and included 6-
month follow-up information. For example, if a patient was initially treated with med-
ication only, but electively revascularized within 6 months, the patient was labelled as
Revascularization. The modiﬁed reference standard was used in all analyses.
The diagnostic model classiﬁes patients in one of the disease categories. Classiﬁcation
is correct if the classiﬁed category matches the underlying truth, and incorrect when
the classiﬁed category does not match the underlying truth. Underlined categories refer
to the underlying ‘true’ disease category, whereas italic categories refer to the disease cat-
egory as classiﬁed by the diagnostic work-up. Individuals classiﬁed as CAD− by the diag-
nostic strategy, who are CAD+ or Revascularization according to their underlying truth
are “under-classiﬁed”. Patients classiﬁed as CAD+ who are Revascularization according
to the underlying truth are “under-classiﬁed”. Individuals classiﬁed as CAD+, who are
CAD− according to the underlying truth, are “over-classiﬁed”. The next paragraph
explains how patients are classiﬁed by the diagnostic work-up.2.3. Short-term decision tree
The SOC-strategy consists of initial evaluation with X-ECG according to the guide-
line [1] (Fig. 1). Non-diagnostic X-ECGs are common (~25% [14])–which warrants fur-
ther testing with pharmacological stress myocardial perfusion imaging (MPI) using
single photon emission CT (SPECT). Patients unable to exercise are evaluated by MPI.
We assume that a CAG classiﬁes patients in the correct category.
The CT-strategy starts with a coronary artery calciﬁcation (CAC) scan in every
patient and a CCTA in patients with a CAC>0 and b400 (Fig. 2). Patients with
CAC=0 and a pre-test probability b70% do not undergo CCTA, because obstructive
CAD is unlikely to be present [15]. This cutoff was chosen to capture the high-risk
patients with typical presentation [16], which is consistent with clinical practice at
our institution. Thus, a patient with zero calcium and a pre-test probability ≥70%
will undergo CCTA (Fig. 2). Based on evidence that revascularization does not always
improve survival beyond optimal medical treatment in patients with moderate disease
[17], the CT-strategy consists of medical treatment for patients with moderate disease
on CCTA and referral to CAG only if the CCTA shows severe CAD (left main-, three
vessel-, or proximal left anterior descending artery disease).2.4. Long-term Markov model
We used a Cox proportional hazards model to estimate the sex-speciﬁc rates of
MACE for CAD−, CAD+, and Revascularization patients in the clinical cohort. Prognosis
after the diagnostic work-up in the model depended on the correct vs incorrect classi-
ﬁcation. Correctly classiﬁed individuals in the model were assigned the adjusted
event rate as observed in the cohort. Under-classiﬁed (and under-treated) individuals
experienced a higher event rate because of the forgone beneﬁt of treatment (hazard
rate ratio (HRR) based on the combined effectiveness of statins [18] and aspirin [19]).
Over-classiﬁcation only occurs when a CAD− patient is classiﬁed as CAD+ and we
assumed that medical treatment does not alter the event rate in these patients. See
supplementary material for more details.
To mimic clinical follow-up of patients with chest pain, we assumed that every
under-classiﬁed patient will be diagnosed with the correct disease category within
the ﬁrst year. We assumed that those patients remain symptomatic prior to the correct
diagnosis because they are under-treated for a short period. As in clinical practice,
patients with persistent angina are re-evaluated by the cardiologist. This implies that
our model assumes that the beneﬁt in terms of better outcomes of a diagnostic strategy
can only be obtained in the ﬁrst year after the initial assessment. In contrast, individ-
uals who are over-classiﬁed are assumed not to reclassify to the CAD− category,
but to remain in CAD+. The negative implications of overestimating the severity of
disease in a CAD− patient consists of extra costs for medication and a (slightly)
lower quality-of-life.
We modeled the risk of dying from non-cardiac causes based on age- and sex-
speciﬁc mortality rates from the Dutch Central Bureau for Statistics [20].
Fig. 1. Further testing algorithm after X-ECG. Italic disease categories refers to classiﬁed category according to the diagnostic work-up. *Low risk DTS=DTS ≥5, intermediate risk
DTS=DTS −10 to 5, high risk DTS=DTS≤−11. DTS: Duke Treadmill Score.
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Costs were based on a previous cost analysis [8] and expert opinion (Table 1),
expressed in 2009 euros. We used the health care perspective according to recommen-
dations for cost-effectiveness analyses [21], and a willingness-to-pay threshold (WTP)
of €80,000/QALY [22]. Medication costs were obtained via a registry provided by the
Dutch Health Care Insurance board [23]. Medication use was based on self-reported
cardiovascular disease-related medication at the time of the last patient contact during
follow-up and assumed to be constant over time.
2.6. Quality-of-life
Age and sex-speciﬁc utilities of the general population [24] were used to model the
quality of life for CAD− patients. For CAD+ and Revascularization patients, the meanFig. 2. Further testing algorithm after CAC. Italic disease categories reﬂect threduction in quality-of-life as compared to the general population was assumed to be
5% and 10%, respectively. Furthermore, under-classiﬁcation (and under-treatment)
was assumed to result in symptoms of angina due to the forgone beneﬁt of anti-
ischemic therapy. Based on reported relative reductions in utility due to anginal symp-
toms, the reduction in quality-of-life was estimated to be 10% [24] and 15% [25] if
under classiﬁcation occurred by 1 or 2 categories, respectively. The quality-of-life of
CAD− patients who are classiﬁed as having CAD+was adjusted to reﬂect the disutility
of taking medication.
2.7. Data analysis
All variables were entered in the model as distributions (Table A2, A3). Outcomes
were calculated as the mean results from probabilistic sensitivity analysis, drawing
random values from the parameter distributions(10,000 samples).e classiﬁed category according to the diagnostic work-up. *See Figure 1.
Fig. 3. Deﬁnition of the disease category, as determined for each patient in the clinical
cohort. Underlined refers to underlying ‘true’ disease category, italic refers to classiﬁed
category according to diagnostic test strategy.
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classiﬁcation. Long-term outcomes included health care costs and quality-adjusted
life years (QALYs). Both future costs and effectiveness were discounted at 3.5% [21].
2.8. Sensitivity analysis
The probability that a strategy was cost-effective was determined by the propor-
tion of simulations in the probabilistic sensitivity analysis that demonstrated cost-
effectiveness for that strategy [26]. Value of information analysis was performed to
determine the value of future research [27].
For the patients in the clinical cohort who did not undergo CAG, disease severity
may have been overestimated by CCTA, which in turn could have caused a bias in
favor of CCTA (since these data were used to determine the probability of correct clas-
siﬁcation, which would turn out high for the CT-strategy). To explore this limitation,
we re-analyzed the model assuming that 40% of CAD+ men and women (randomly
selected) who did not undergo CAG would actually be CAD− patients. Furthermore, we
re-analyzed the model assuming that a proportion of patients with abnormal X-ECG
would not be referred for CAG.
3. Results
3.1. Short-term analysis
Analysis of the short-term model revealed that the average diag-
nostic costs for the SOC-strategy were €739 (95%CI:547–978) and
€526 (95%CI:€395–684) for men and women, respectively. The CT-Table 2
Short-term results(men).
SOC-strategy
Disease categorya CAD– CAD+ Revasc.
CAD− 0.55 0.05 –
CAD+ 0.07 0.10 –
Revascularization 0.04 0.01 0.18
Mean 95%CIb
Diagnostic costs(euros) 739 547; 978
Pre-testb70% 509 372; 681
Pre-test≥70% 1206 873; 1617
% Correctly classiﬁedd 0.83 0.80; 0.87
Pre-testb70% 0.82 0.77; 0.87
Pre-test≥70% 0.85 0.79; 0.89
Radiation exposuree(mSv) 6.2 4.5; 8.3
Pre-testb70% 4.1 2.9; 5.6
Pre-test≥70% 10.4 7.5; 13.9
SOC,standard-of-care;CT;computed tomography; Revasc.,revascularization;CI,conﬁdence in
a See Fig. 3.
b Based on a probabilistic sensitivity analysis (10,000 samples).
c Difference applies to the number of correctly classiﬁed patients in that category.
d Correct classiﬁcation by the diagnostic strategy.
e Radiation exposure related to diagnostic imaging.strategy cost €494 (95%CI:€375–641) and €274 (95%CI:€205–356)
for men and women, respectively (Tables 2, 3). The SOC-strategy clas-
siﬁed 83% (95%CI:80–87%) of men correctly, whereas the CT-strategy
classiﬁed 82% (95%CI:77–85%) correctly. The SOC-strategy classiﬁed
85% (95%CI:82–88%) of women correctly, whereas the CT-strategy
classiﬁed 88% (95%CI:85–92%) correctly.
3.1.1. Subgroup analysis
For men with a pre-test probability of b70% and ≥70%, diagnostic
cost-savings for the CT-strategy as compared to SOC were−€211 and
−€312, respectively. In men with a pre-test probability ≥70%, the
percentage correctly classiﬁed by CT was 11% lower compared to
SOC (Table 2).
When re-analyzing women with a pre-test probability of b70%
and ≥70%, diagnostic cost-savings for the CT-strategy as compared
to SOC were −€234 and −€317, respectively (Table 3).
3.2. Long-term analysis
Analysis of the long-term model demonstrated a small gain in
average quality-adjusted life years (QALYs)(+0.002, +0.004) and a
decrease in health care costs(−€229, −€444) for the CT-strategy as
compared with SOC, for men and women respectively (Tables 4, 5).
Therefore, the CT-strategy is superior to the SOC-strategy(more effec-
tive and less expensive, SOC is dominated).
3.2.1. Subgroup analysis
For men with a pre-test probability of b70%, the difference in
health care costs and effectiveness for the CT-strategy compared
with SOC was −€227 and +0.004 QALY, respectively. For men with
a pre-test probability of ≥70%, this difference was −€231 and
−0.003 QALY, respectively (Table 4, Fig. 4).
For women with a pre-test probability of b70%, the difference in
health care costs and effectiveness for the CT-strategy compared
with SOC was −€444 and +0.004 QALY, respectively. For women
with a pre-test probability of ≥70%, this difference was −€782 and
+0.006 QALY, respectively (Table 5, Fig. 5).
3.3. Sensitivity analysis
In probabilistic sensitivity analysis the probability that the CT-
strategy was cost-effective was 100% in all subgroups, except forCT-strategy Difference(CT vs. SOC)
CAD– CAD+ Revasc. Mean 95%CIb
0.56 0.04 – +0.01c −0.01; +0.03
0.04 0.14 – +0.03c +0.01; +0.06
0.04 0.06 0.12 −0.06c −0.09; −0.03
Mean 95%CIb Mean 95%CIb
494 375; 641 −245 −560; −117
298 223; 390 −211 −357; −87
894 654; 1197 −312 −516; −146
0.82 0.78; 0.85 −0.01 −0.06; +0.02
0.85 0.80; 0.89 +0.03 −0.02; +0.07
0.74 0.66; 0.82 −0.11 −0.19; −0.03
5.7 4.4; 7.1
4.1 3.1; 5.3
8.9 6.9; 11.2
terval.
Table 3
Short-term results(women).
SOC-strategy CT-strategy Difference(CT vs. SOC)
Disease categorya CAD− CAD+ Revasc. CAD− CAD+ Revasc. Mean 95%CIb
CAD− 0.77 0.07 – 0.80 0.04 – +0.03c +0.01; +0.05
CAD+ 0.05 0.03 – 0.02 0.05 – +0.02c +0.01; +0.04
Revascularization 0.03 0.00 0.05 0.02 0.04 0.03 −0.02c −0.04; −0.01
Mean 95%CIb Mean 95%CIb Mean 95%CIb
Diagnostic costs(euros) 526 395; 684 274 205; 356 −252 −398; −127
Pre-testb70% 447 329; 596 213 157; 280 −234 −368; −113
Pre-test≥70% 796 581; 1057 480 340; 652 −317 −542; −123
% Correctly classiﬁedd 0.85 0.82; 0.88 0.88 0.85; 0.92 +0.03 −0.00; +0.06
Pre-testb70% 0.87 0.83; 0.90 0.89 0.85; 0.93 +0.02 −0.01; +0.06
Pre-test≥70% 0.81 0.75; 0.85 0.86 0.78; 0.92 +0.05 −0.03; +0.12
Radiation exposuree(mSv) 5.1 3.6; 7.0 4.1 3.1; 5.3
Pre-testb70% 3.9 2.7; 5.4 3.3 2.4–4.3
Pre-test≥70% 9.3 6.4–12.8 6.7 5.1–8.6
SOC,standard-of-care;CT;computed tomography; Revasc.,revascularization;CI,conﬁdence interval.
a See Fig. 3.
b Based on a probabilistic sensitivity analysis (10,000 samples).
c Difference applies to the number of correctly classiﬁed patients in that category.
d Correct classiﬁcation by the diagnostic strategy.
e Radiation exposure related to diagnostic imaging.
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of information analysis suggested no value for future research, except
for men with a pre-test probability ≥70%.
The short-term diagnostic costs were insensitive to changes in
underlying disease status based on CT(not shown). In men, the
long-term cost-savings were reduced from −€229 (reference
case) to −€135, and there was no longer a difference in QALYs.
For men with a pre-test probability b70%, long-term cost-savings
were reduced from −€227 to −€95, and for men with a pre-test
probability ≥70% from −€231 to −€217. In women, the long-
term cost-savings were reduced from −€444(base case) to −€296
and the net gain in QALYs was reduced from +0.004 (reference
case) to +0.003.
Short-term diagnostic costs for SOC were lowered when a propor-
tion of patients with abnormal X-ECG would not undergo CAG, which
reduced cost savings for CT. However, long-term costs were increased
for SOC (due to over treatment in patients with false-positive X-ECG
and follow-up testing), which was in favor of CT.Table 4
Long-term results(men).
SOC-strategy C
Mean 95%CIa M
Health care costs(euros) 12,969 10,170; 17,764 1
Pre-testb70% 9691 7670; 12,588 9
Pre-test≥70% 19,740 14,439; 30,323 1
Effectiveness(QALYs) 11.671 11.079; 12.158 1
Pre-testb70% 11.980 11.505; 12.403 1
Pre-test≥70% 11.025 9.935; 11.703 1
Radiation(mSv) 9.5 7.1; 12.3 8
Pre-testb70% 6.5 4.7; 8.8 5
Pre-test≥70% 15.6 11.8; 20.1 1
ICER(mean) Dominated S
Pre-testb70% Dominated S
Pre-test≥70% 30,406 -
Probability
cost-effective(%)b
1 9
Pre-testb70% 0 1
Pre-test≥70% 41 5
SOC,standard-of-care;CT;computed tomography;CI,conﬁdence interval;ICER,incremental co
a Based on a probabilistic sensitivity analysis (10,000 samples).
b Proportion of simulations that showed the CT-strategy to be cost-effective, using a will4. Discussion
4.1. Summary
We explored a hypothetical CT-strategy for its potential effective-
ness and costs compared to SOC based on current guidelines for
patients with stable chest pain.
Short-term results suggest that the CT-strategy is less expensive
compared to SOC. This is explained by the fact that fewer patients
undergo subsequent MPI or CAG, which are costly. Simultaneously,
our results suggest that CT is more effective in correctly classifying
patients, except for men with a pre-test probability ≥70%. Men with
a pre-test probability ≥70% are more often correctly classiﬁed using
SOC, because patients in the SOC-strategy are more often referred
for CAG immediately after an abnormal test (which results in correct
classiﬁcation).
Long-term analyses demonstrated that the CT-strategy was
slightly more effective and less costly compared to the SOC-strategy.T-strategy Difference (CT vs. SOC)
ean 95%CIa Mean 95%CIa
2,740 9957; 17,486 −229 −554; −84
464 7457;12,368 −227 −399; −56
9,509 14,242; 29,952 −231 −448; −41
1.672 11.078; 12.160 +0.002 −0.002; +0.004
1.984 11.510; 12.406 +0.004 +0.001; +0.007
1.022 9.926; 11.703 −0.003 −0.011; +0.002
.4 6.6; 10.4
.5 4.2; 7.0
4.2 11.1; 17.9
uperior
uperior
9
00
9
st-effectiveness ratio.
ingness-to-pay threshold of €80.000/QALY.
Table 5
Long-term results(women).
SOC-strategy CT-strategy Difference (CT vs. SOC)
Mean 95%CIa Mean 95%CIa Mean 95%CI
Health care costs(euros) 8513 6977; 10,574 8068 6520; 10,134 −444 −696; −219
Pre-testb70% 7808 6303; 9792 7464 5964; 9457 −344 −582; −119
Pre-test≥70% 10,896 8292; 14,736 10,112 7474; 13,986 −782 −1319; −327
Effectiveness(QALYs) 12.684 12.269; 13.097 12.689 12.273; 13.101 +0.004 +0.002; +0.007
Pre-testb70% 12.727 12.306; 13.139 12.731 12.310; 13.144 +0.004 +0.002; +0.006
Pre-test≥70% 12.537 12.018; 12.998 12.543 12.023; 13.004 +0.006 +0.000; +0.012
Radiation(mSv) 6.8 4.9;9.1 5.2 4.0;6.7
Pre-testb70% 5.6 3.9;7.8 4.3 3.2;5.6
Pre-test≥70% 11.0 7.7; 15.0 8.4 6.2; 10.9
ICER(mean) Dominated Superior
Probability
cost-effective(%)b
0 100
SOC,standard-of-care;CT;computed tomography;CI,conﬁdence interval;ICER,incremental cost-effectiveness ratio
a Based on a probabilistic sensitivity analysis (10,000 samples).
b Proportion of simulations that showed CT-strategy to be cost-effective, using a willingness-to-pay threshold of €80.000/QALY.
1273T.S.S. Genders et al. / International Journal of Cardiology 167 (2013) 1268–1275Results were altered when the (potential) degree of disease severity
overestimation by CCTA was taken into account. Because cost savings
were robust, the CT-strategy remained favorable even when the CT-
strategy resulted in fewer QALYs, for example in men with a pre-
test probability ≥70%. Results for CT were more favorable in
women, which is explained by the lower prevalence of disease in
women and the higher prevalence of zero calcium.
As expected, the gain in QALYs for the CT-strategy is small, since
patients with persistent complaints will return to their physician
until symptoms are treated adequately. The model assumes that
within one year, all patients who are under–treated become appro-
priately treated. A beneﬁt was gained from avoiding lifelong medica-
tion (over-treatment) in a substantial proportion of cases but this
mainly affects costs. Nevertheless, even if the gain in QALYs is very
small or close to zero, the CT-strategy remains optimal because it is
less costly. Furthermore, several expected additional beneﬁts of the
CT-strategy were not incorporated in the model, such as a reduced
total time to ﬁnal diagnosis and a reduction in additional downstream
health care costs through a more expedient work-up. In addition,
since the negative predictive value of CCTA is higher compared to
X-ECG, physicians can be more conﬁdent in reassuring a patient
after a negative CCTA.4.2. Previous publications
Previous reports based on patient-level data from the US indicated
that CCTA compared with SPECT reduces 1-year CAD-related health
care expenditures (based on administrative databases and Medicare
reimbursements) by 26% in a low risk population [28,29]. NoFig. 4. Incremental costs and effectiveness of the CT-strategy as compared with SOC; re-
sults from a probabilistic sensitivity analysis (10,000 samples) inmen. Blue squares (right
cloud) indicate results for men with a pre-test probability b70% and pink squares (left
cloud) indicate men with a pre-test probability ≥70%. The dotted line represents the
willingness-to-pay threshold of €80.000/QALY.differences in clinical outcomes were observed. These reports ana-
lyzed 1-year outcomes of patients who underwent CCTA and who
were matched to a cohort that underwent SPECT, whereas the current
study analyzed the long-term outcomes of a pre-speciﬁed diagnostic
protocol for patients presenting with chest pain. Furthermore, the
current analysis is based on a cohort of patients who underwent
both CCTA and X-ECG. In spite of these differences, the main conclu-
sion is the same, namely that CT is cost-saving and equally effective
as compared to SOC. However, other reports suggest that using
CCTA increases costs as compared with MPI [30,31].
Lastly, a recent cost-effectiveness analysis which compared sever-
al CCTA-based strategies with myocardial perfusion SPECT and direct
CAG found that the CCTA-based strategies were optimal up to a prev-
alence of CAD of 80% [32].4.3. Limitations
Firstly, not all patients in the cohort underwent CAG. CCTA may
have caused an overestimation of disease in these patients. To over-
come this limitation, we included 6-months follow-up data in our ref-
erence standard in determining the disease category. Furthermore,
we performed a sensitivity analysis to explore the magnitude of pos-
sible bias due to overestimation of disease by CCTA.
Secondly, we only observed the prognosis of patients who under-
went both CCTA and X-ECG. Treatment decisions were based on the
ﬁndings of both CCTA and X-ECG. We assumed that correctly classi-
ﬁed patients would have a similar prognosis to that observed within
follow-up of the clinical cohort. For patients incorrectly classiﬁed,
however, prognosis was not observed. Therefore, several assumptionsFig. 5. Incremental costs and effectiveness of the CT-strategy as compared with SOC; re-
sults from a probabilistic sensitivity analysis (10,000 samples) in women. Blue squares
(upper cloud) indicate results for women with a pre-test probability b70%, pink squares
(lower cloud) indicate women with a pre-test probability ≥70%. The dotted line repre-
sents the willingness-to-pay threshold of €80.000/QALY.
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were made to estimate the prognosis of incorrectly classiﬁed patients.
Thirdly, model parameters were based on the patient cohort
where possible, whereas best-available evidence from the literature
was used otherwise. For example, we modeled the effect of SPECT
using sensitivity and speciﬁcity as reported in a meta-analysis [33].
Fourthly, CCTA involves the possibility of incidental ﬁndings,
which can occur in up to 28% of CCTAs [34,35]. As of today, it is
unclear whether it is useful or cost-effective to follow up on inciden-
tal ﬁndings. Moreover, the associated ethical and legal issues are dif-
ﬁcult(if not impossible) to incorporate in a decision model. Also,
although we estimated the radiation exposure, we did not model
the harmful effects. Since the difference in radiation exposure be-
tween the two strategies was small, this is unlikely to have an effect
on the optimal decision.
4.4. Generalizability
Our analysis was based on a real-world Dutch population and
Dutch cost estimates, which limits the generalizability. Nevertheless,
in probabilistic sensitivity analysis we explored the effect of the
uncertainty around our parameter inputs and found that our results
were robust for all women and for men with a prior probability
b70%. Furthermore, we compared only two strategies that reﬂect cur-
rent practice at our institution. Other hospitals may have a different
standard-of-care, which could alter the conclusion about the compar-
ative effectiveness and costs.
4.5. Future research
Our analysis suggests that the CT-strategy is superior to SOC.
However, the data in the model was based on a non-randomized
observational study in which patients were prospectively recruited
to undergo both tests. We did not directly observe the prognosis of
patients who underwent X-ECG or CCTA only but instead estimated
their prognosis with a decision model. A RCT would give valuable
insight regarding outcomes and costs for both diagnostic strategies
separately. In lieu of such a trial, this study provides preliminary esti-
mates of the outcomes for a CT-strategy as compared with SOC. Our
results can be used to make decisions regarding CT for patients
presenting with stable chest pain, as long as RCTs with long-term
follow-up are on-going. Furthermore, our results suggest that future
research would mainly be beneﬁcial for the decision regarding men
with a pre-test probability ≥70%.
5. Conclusion
Analysis of our model suggests that a diagnostic strategy using ini-
tial evaluation with CT is less expensive and equally effective as com-
pared to SOC, which was most pronounced for men with atypical
symptoms and all women irrespective of their presenting symptoms.
Although the results were robust, randomized controlled trials with
long-term follow-up are needed to conﬁrm our results.
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